AlphaCentric Advisors LLC Buys New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AlphaCentric Advisors LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 9,000 shares of the medical equipment provider’s stock, valued at approximately $988,000.

A number of other institutional investors also recently modified their holdings of the stock. Moloney Securities Asset Management LLC acquired a new position in shares of Lantheus during the 3rd quarter valued at $1,066,000. Citizens National Bank Trust Department lifted its position in shares of Lantheus by 2.4% during the 3rd quarter. Citizens National Bank Trust Department now owns 12,798 shares of the medical equipment provider’s stock valued at $1,405,000 after acquiring an additional 298 shares during the period. Van ECK Associates Corp lifted its position in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of Lantheus by 56.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 128,913 shares of the medical equipment provider’s stock valued at $14,148,000 after acquiring an additional 46,262 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in shares of Lantheus by 226.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 526 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $115.45 on Tuesday. The firm has a market cap of $8.02 billion, a price-to-earnings ratio of 18.93 and a beta of 0.51. The company has a fifty day moving average price of $108.30 and a 200-day moving average price of $95.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Analyst Ratings Changes

Several research firms have weighed in on LNTH. JMP Securities lowered their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Leerink Partners upped their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Finally, Truist Financial lowered their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.